Source comparison
Ipamorelin vs Hexarelin for Research UK 2026
All compounds discussed in this article are intended exclusively for laboratory and preclinical research purposes. None of the peptides referenced here are approved for human administration, therapeutic use, or clinical application. This content is directed at
This comparison does not assign a generated winner or score.
- All compounds discussed in this article are intended exclusively for laboratory and preclinical research purposes. None of the peptides referenced here are approved for human administration, therapeutic use, or clinical application. This content is directed at qualified researchers operating within appropriate regulatory and ethical frameworks.
- Ipamorelin and Hexarelin are both GH secretagogue receptor (GHS-R1a) agonists, but their pharmacological profiles diverge significantly beyond their shared GHS-R1a activity: Ipamorelin is a highly selective GHS-R1a agonist with minimal off-target activity, while Hexarelin activates GHS-R1a and additionally engages CD36 (scavenger receptor B2) — a second receptor that mediates Hexarelin’s cardioprotective and adipose biology independently of GH secretion. This comparison is mechanistically distinct from the Ipamorelin vs Hexarelin post (ID 77402, which covers GHS-R1a selectivity broadly), the Hexarelin cardiac post (ID 77046), the Ipamorelin bone post (ID 77151), and the GH secretagogue hub (ID 77059) — this comparison focuses specifically on the CD36 receptor as the defining mechanistic divergence between these two peptides, what CD36-mediated biology provides that GHS-R1a-only biology cannot, and the research design implications of choosing one over the other.